About Us

  • BlinkBio is a biotechnology company formed to exploit Bioorthogonal Linker (“BLink”) chemistries through our Tunable Drug Conjugates (TDCs) platform for the treatment of oncology and other diseases.

  • The development of antibody (ADC) and small molecule (SMDC) drug conjugates has already provided a valuable contribution to the treatment of cancer by enabling the targeted delivery of therapeutic “payloads” inside cancer cells. However, there remains room for improvement. For example, ADCs stay in the body for many days, creating a need for stable linkers to limit toxic side-effects from systemic release of payload, and there are challenges in making multi-payload SMDCs.

    At BlinkBio, we have assembled a proprietary suite of assets for the development of Tunable Drug Conjugates (TDCs) that use a differentiated rapid payload release/rapid systemic clearance approach intended to drive high payload concentrations within tumor cells while minimizing toxicities to patients. The Company has deployed proprietary Silicon based linker chemistries in the development of a unique SiLinker and Payload Cassette platform for incorporation into our TDCs. The licensing of the exclusive Dual variable Domain-Fab (DVD-Fab) targeting capability from The Scripps Research Institute (TSRI) provides a proprietary means of specifically binding a broad array of cell surface proteins with the aim of delivering powerful anti-cancer medicines inside the tumor cell and within the tumor microenvironment. DVD-Fab containing TDCs are also expected to be cleared from the body within hours, enabling better management of side-effects.

    BlinkBio’s business strategy is focused on developing selected TDCs through clinical development while seeking partnerships with major pharmaceutical and biotech companies to broaden the utility and application of these novel drug conjugates in improving treatment outcomes for patients worldwide.